Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Marginal Zone Lymphoma

B-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Bendamustine Hydrochloride

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2

Rituximab and Bendamustine

Carlos Montalbán, MD

Antonio Salar, MD

Ana Muntañola, MD

Mª José Rodríguez, MD

María José Terol, MD

Juan Manuel Sancho, MD

Eva Domingo, MD

Grande Carlos, MD

Carlos Panizo, MD

Miguel Canales, MD

Raquel Oña, MD

Reyes Arranz, MD

Dolores Caballero, MD

José Luis Bello, MD

Joan Bargay, MD

Luis Palomera, MD

Franciaco Javier Peñalver, MD

Eulogio Conde, MD

José Javier Sánchez-Blanco, MD

Concepción Nicolás, MD

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.

Primary endpoint:

* Event-free-survival (EFS) (failure or death from any cause) for all patients.

Secondary endpoints:

* Complete and partial remission rates for all patients
* Response duration (time to relapse or progression) for responder patients
* Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
* Overall survival for all patients
* Acute and long-term toxicity

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Behaviors and Mental Disorders

Aggression

Bendamustine

Martin Mohren, PD

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation. Aim is to find response rates and duration of combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD 20 positive B cell NHL.

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.

University of Magdeburg

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	NCT01015248	MALT LYMPHOMA	Rituximab and B...	18 Years - 84 Years	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL	NCT00385125	Lymphoma, High-...	Bendamustine Rituximab	18 Years -	University of Magdeburg
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL	NCT00385125	Lymphoma, High-...	Bendamustine Rituximab	18 Years -	University of Magdeburg
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	NCT01015248	MALT LYMPHOMA	Rituximab and B...	18 Years - 84 Years	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Spots Global Cancer Trial Database for cd 20 positive